| This is the talk page for discussing improvements to the HBL20017 article. This is not a forum for general discussion of the subject of the article. |
Article policies
|
| Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
HBL20017
editDisclosure: I have a conflict of interest because I am directly involved in the research/development of HBL20017. I am not requesting promotional changes, only correction of factual inaccuracies.
[1] Current Text: It was developed by Negev Labs and Parow Entheobiosciences.[1]
Problem: The cited sources do not appear to support this wording. The available sources indicate involvement of Hadassah BrainLabs and Negev Labs, while Parow Entheobiosciences is acknowledged in relation to implementation of the SAPAP3-KO model.[1]
Proposed replacement: It was developed by Hadassah BrainLabs with support from Negev Labs. Parow Entheobiosciences supported implementation of the SAPAP3-KO model.[1]
[2] Current Text: HBL20017 was first described in the scientific literature by Alan P. Kozikowski and colleagues in December 2024.[1],[2]
Problem: The cited abstract lists Bernard Lerer as first author[1]
Proposed replacement: ‘HBL20017 was first described in the scientific literature by Bernard Lerer and colleagues in December 2024.[1],[2]
Source: [1] Lerer B, Golding P, Brownstien M, Kozikowski A, Lifschytz T (December 2024). "ACNP 63rd Annual Meeting: Poster Abstracts P609-P914: P660. A Novel, Non-Hallucinogenic Psychedelic for the Treatment of Obsessive-Compulsive Disorder [2] Compounds and uses thereof as modulators of serotonin receptors". Google Patents. 10 April 2025. Retrieved 4 April 2026.
I request that an uninvolved editor review and make these correction if appropriate. LLBern (talk) 12:46, 17 May 2026 (UTC)